|
Using the Carcinogenicity Potency Categorization Algorithm to Predict N-Nitrosamine Carcinogenicity -Webinar
|
|
0
|
306
|
May 13, 2024
|
|
🇺🇸 FDA - Updated information on recommended AI for NDSRIs (23/Feb/2024) - Tables 2 & 3
|
|
15
|
2734
|
May 12, 2024
|
|
APIC NA Risk Assessment Template
|
|
5
|
2671
|
May 11, 2024
|
|
Autonomous CPCA Web-based calculator FREE
|
|
28
|
4480
|
May 2, 2024
|
|
N-nitroso-rivaroxaban amide
|
|
5
|
1038
|
April 27, 2024
|
|
Nitrosamine testing results
|
|
10
|
850
|
April 18, 2024
|
|
🇸🇦 Saudi FDA requesting Nitrosamines Risk Assessments
|
|
2
|
1275
|
April 17, 2024
|
|
Clinico-pathological correlations after intake of potentially nitrosamine/ NDSRIs contaminated drugs
|
|
1
|
261
|
April 14, 2024
|
|
Nitrosamines: A new systematic review
|
|
11
|
2774
|
April 14, 2024
|
|
Whether N-Nitroso Dicyclomine possible?
|
|
1
|
398
|
April 12, 2024
|
|
N-Nitroso Edoxaban Desmethyl Impurity CPCA Score
|
|
6
|
924
|
April 8, 2024
|
|
Request for risk assessment and confirmatory testing for nortriptyline containing products
|
|
4
|
543
|
April 3, 2024
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
82
|
9130
|
April 1, 2024
|
|
Risk Assessment Study of Nitrosamines for the API Temozolomide Industrial Process -Pub
|
|
1
|
1354
|
February 6, 2024
|
|
Antioxidant as a risk mitigation strategy
|
|
5
|
609
|
March 28, 2024
|
|
Chemistry of N-Nitroso Ivacaftor
|
|
5
|
776
|
March 25, 2024
|
|
AI difference between FDA and EMA, HC and TGA
|
|
0
|
930
|
March 22, 2024
|
|
IVACAFTOR (N-Nitroso Ivacaftor)
|
|
0
|
313
|
March 22, 2024
|
|
Application of duplex sequencing to evaluate mutagenicity -Pub
|
|
1
|
299
|
March 14, 2024
|
|
🇪🇺 OMCL Network published NDSRIs Analytical Methods
|
|
1
|
1038
|
March 11, 2024
|
|
Simple and Practical Method for the Quantitative High-Sensitivity Analysis of N-Nitroso Duloxetine in Duloxetine Drug Products Utilizing LC-MS/MS
|
|
0
|
481
|
March 9, 2024
|
|
AI limit for N-Nitroso Losartan
|
|
4
|
457
|
March 9, 2024
|
|
Is it possible to observe N-nitrosamines formation from oximes? Do you have any reference to support the risk assessment for nitrosamine formation from the reaction of these functional groups in the presence of nitrosating agents? Thank you
|
|
2
|
266
|
February 27, 2024
|
|
In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study Using the Software Program Zeneth
|
|
3
|
350
|
February 24, 2024
|
|
Testig method for nitroso Ciprofloxacin
|
|
12
|
1243
|
February 16, 2024
|
|
NDSRIs standards (for confirmatory testing or ames/other tests)
|
|
15
|
1329
|
February 14, 2024
|
|
Defining nitrosamine acceptable intake based on technical feasibible limit rather than CPCA
|
|
6
|
415
|
February 11, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
410
|
February 8, 2024
|
|
Aromatic nitrogen "Is it possible for aromatic nitrogen to convert nitrosamine?"- Indole
|
|
10
|
1852
|
February 2, 2024
|
|
Swissmedic updated requirements for dealing with potential nitrosamine impurities in medicinal products
|
|
2
|
316
|
February 1, 2024
|